Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Toronto Dominion Bank

Toronto Dominion Bank increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 19.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 115,232 shares of the medical equipment provider's stock after purchasing an additional 18,526 shares during the quarter. Toronto Dominion Bank's holdings in Hologic were worth $9,387,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. State Street Corp lifted its position in shares of Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock worth $847,944,000 after buying an additional 81,057 shares during the last quarter. FMR LLC boosted its stake in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after acquiring an additional 2,174,093 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock worth $208,051,000 after purchasing an additional 18,774 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock worth $200,952,000 after purchasing an additional 195,285 shares during the last quarter. Finally, Black Creek Investment Management Inc. increased its position in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock worth $173,669,000 after purchasing an additional 885,524 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX stock traded down $1.44 on Friday, reaching $73.65. 2,553,425 shares of the company's stock were exchanged, compared to its average volume of 1,626,827. The stock has a fifty day moving average of $79.32 and a 200-day moving average of $78.56. The firm has a market cap of $16.71 billion, a PE ratio of 22.12, a P/E/G ratio of 2.38 and a beta of 0.96. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a twelve month low of $70.24 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts' consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 EPS. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Leerink Partners dropped their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. JPMorgan Chase & Co. increased their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.